Cleo Diagnostics (ASX:COV) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cleo Diagnostics's EBITDA for the six months ended in Dec. 2023 was A$-2.56 Mil. Cleo Diagnostics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Cleo Diagnostics's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Cleo Diagnostics EBITDA Margin % Historical Data

The historical data trend for Cleo Diagnostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics EBITDA Margin % Chart

Cleo Diagnostics Annual Data

Trend

Jun23

EBITDA Margin %

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
EBITDA Margin %	-	-	-

Competitive Comparison of Cleo Diagnostics's EBITDA Margin %

For the Medical Devices subindustry, Cleo Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's EBITDA Margin % falls into.

Cleo Diagnostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cleo Diagnostics's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-1.575	/	0
	=	%

Cleo Diagnostics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.555	/	0
	=	%

Cleo Diagnostics (ASX:COV) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cleo Diagnostics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines